lenalidomide,tafasitamab,Pelabresib,Ruxolitinib
incyte,morphosys,Novartis
['#myelof', 'dlbcl', 'l-mind', 'morphosys']
we re presenting data from the phase 2 manifest and l-mind studies at #eha2023. join our poster presentations to learn about the results in #myelofibrosis and relapsed or refractory #dlbcl. 
Global commercial-stage biopharmaceutical company driven by our mission: More life for people with cancer. https://t.co/IMbjQ1Ym1Z